Skip to content

Cervical Cancer Health Center

Font Size

Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Cervical Cancer

No standard treatment is available for patients with recurrent cervical cancer that has spread beyond the confines of a radiation or surgical field. For locally recurrent disease, pelvic exenteration can lead to a 5-year survival rate of 32% to 62% in selected patients.[1,2] These patients are appropriate candidates for clinical trials testing drug combinations or new anticancer agents.

The Gynecologic Oncology Group (GOG) has reported on several randomized phase III trials, (GOG-0179 [NCT00003945], GOG-0240 [NCT00803062]) in this setting. Single-agent cisplatin administered intravenously at 50 mg/m² every 3 weeks was the most-used regimen to treat recurrent cervical cancer since it was initially introduced in the 1970s.[3,4]

Recommended Related to Cervical Cancer

Understanding Cervical Cancer -- the Basics

Cervical cancer is cancer of the cervix, the narrow neck at the lower part of a woman's uterus, just above the vagina (Figure 1). The cervix connects the uterus to the vagina. Approximately eight out of 10 cervical cancers originate in surface cells lining the cervix (squamous cell carcinomas). These cancers do not form suddenly. Over time, healthy cervical cells can become abnormal in appearance -- this is called dysplasia. Although these cells are not cancerous, they can eventually become...

Read the Understanding Cervical Cancer -- the Basics article > >

Various combinations containing cisplatin [3,4] failed to reach their primary endpoint of improving survival, however, a doubling of the cisplatin dose-rate did improve survival. Combinations with paclitaxel and with ifosfamide improved response rates (RR), but they did so at a cost of much greater toxicity, especially with the latter drug. A survival advantage over cisplatin was obtained with the cisplatin + topotecan (CT) doublet [4] leading to approval of this indication for topotecan by the Food and Drug Administration. However, in this study, cisplatin underperformed because many patients had received this drug earlier as a radiosensitizer. (Refer to Stages IIA, IIB, III, and IVA for more information on chemoradiation and the drug cisplatin, in particular.). Therefore, cisplatin plus paclitaxel (CP) was chosen as the reference arm in GOG-0204 (NCT00064077).

The GOG has reported on sequential randomized trials dealing with chemotherapy for stage IVB, recurrent, or persistent cervical cancer.[4,5,6,7,8] In the initial trial, the primary endpoint of exceeding the survival observed with cisplatin alone was not reached. However, in these trials:

  • The ifosfamide + cisplatin combination was superior to cisplatin alone in the secondary endpoint of RR but at the cost of increased toxicity.
  • The paclitaxel + cisplatin (PC) combination, similarly, was superior in RR and progression-free survival (PFS), and its toxicity was similar to the single agent except in patients with GOG performance status 2 (scale: 0, asymptomatic–4, totally bedridden).
  • The CT doublet combination had a significant advantage in overall survival (OS) compared with cisplatin alone, but cisplatin alone underperformed in this trial because as many as 40% of the patients had already received cisplatin up front as a radiosensitizer.
    Next Article:

    Today on WebMD

    cancer cell
    HPV is the top cause. Find out more.
    doctor and patient
    Get to know the Symptoms.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
    Integrative Medicine Cancer Quiz
    Lifestyle Tips for Depression Slideshow
    Screening Tests for Women
    what is your cancer risk